

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of**  
**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) January 8, 2018**

---

**IRIDEX CORPORATION**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-27598**  
(Commission  
File Number)

**77-0210467**  
(IRS Employer  
Identification No.)

**1212 Terra Bella Avenue**  
**Mountain View, California 94043**  
(Address of principal executive offices, including zip code)

**(650) 940-4700**  
(Registrant's telephone number, including area code)

**Not Applicable**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 2.02. Results of Operations and Financial Condition.**

On January 8, 2018, IRIDEX Corporation announced its anticipated revenues and Cyclo G6 glaucoma laser system and G6 probe shipments for the fourth quarter and full year ended December 30, 2017. A copy of the Company's press release announcing such results dated January 8, 2018 is attached as Exhibit 99.1.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release dated January 8, 2018.</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IRIDEX CORPORATION**

By: /s/ William M. Moore  
William M. Moore  
President and Chief Executive Officer

Date: January 8, 2018



## IRIDEX Announces Preliminary Operational and Financial Results for 2017 Fourth Quarter and Full Year

MOUNTAIN VIEW, Calif., January 8, 2018 -- IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 30, 2017.

### Highlights

- Total revenue for the fourth quarter of 2017 expected to be \$11.0 to \$11.1 million
- Total revenue for 2017 expected to be \$42.3 to \$42.4 million
- Approximately 133 Cyclo G6 glaucoma laser systems and 10,600 G6 probes were shipped in the fourth quarter of 2017
- Approximately 377 Cyclo G6 glaucoma laser systems and 32,100 G6 probes were shipped in 2017

"I'm encouraged by the momentum of our G6 platform in the second half of 2017. In the fourth quarter we set records for G6 system and G6 probe shipments, which was primarily driven by our performance in the U.S. market. Our retina business in the fourth quarter had nice demand but was impacted by some product shipment issues which impacted our total revenues. We are working diligently to address those issues," said William M. Moore, President and CEO. "The impact of the G6 platform on our sales model has been meaningful, as it continues to positively transform our business and importantly, the way physicians are able to treat their glaucoma patients. We plan to continue our focus on the opportunity we see with our G6 platform."

IRIDEX expects to release its complete fourth quarter and full year 2017 results in early March 2018, at which time, the Company plans to provide guidance for full year 2018.

### About IRIDEX

IRIDEX Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX's current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. IRIDEX products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the IRIDEX website at <http://www.iredex.com/>.

### Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the Company's anticipated revenue and Cyclo G6 system and probe shipments for fourth quarter and full year 2017, the timing of the release of the Company's complete financial results for fourth quarter and full year 2017 and guidance for full year 2018, and the impact of the G6 platform on the Company's sales model and business and on glaucoma treatment. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of

---



which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.

**Investor Relations Contact**

Lynn Pieper Lewis or Leigh Salvo  
(415) 937-5404  
[investors@iridex.com](mailto:investors@iridex.com)